Through 20 years of experience in Consumer Goods (FMCG) and pharmaceutical industry (CDMO), he developed his international expertise in Operations, Finance, Supply chain and Sales. During 14 years, he worked for Danone Group in different countries (Iran, Denmark and Germany) where he ensured several finance positions (from business controlling to finance director). Back in Belgium, he joined Cenexi Laboratoires Thissen, a CDMO specialized in oncology, He worked more than 6 years in the manufacturing site. He started as finance director and then became Supply Chain and Customer services director. He holds a Master in Management from the University of Louvain-la-Neuve (Louvain School of Management – previously IAG).
After a MSc. in physics at the University of Namur, Adrien worked as a teaching assistant at the engineering faculty of the Université libre de Bruxelles. Leaving this position, he worked as project manager at Mecasoft, a company specialized in precision machining, for the development of the micro-machining division on medical, aerospace and microfluidics applications, among others. He joined the Carmapharm project in 2014 to work on the development of microfluidics in the team of Prof. B. Scheid.
After a MSc. in chemical engineering from the Ecole Centrale Marseille and another in organic chemistry from the Aix-Marseille university, Jean obtained his PhD in chemical sciences developing continuous flow chemical routes for active pharmaceutical ingredients with UCB as part of the Legomedic project. He worked as a post-doctoral researcher on convergent CO2-metal capturing processes in continuous flow under the supervision of Prof. J.Leclaire and Dr. Claude de Bellefon. He then joined the team of Prof. B. Scheid in 2018 to participate in the Legomedic project.
After completing his PhD at the Vrije Universiteit Brussel at the faculty of engineering on newly developed flame retardants, Bart worked for Benelux-Scientific, a vendor of analytical equipment for material characterization. Leaving this position, he led the “Flanders Microreactor and Microfluidics Consortium” or FMMC, where he was in contact with a vast network of technology innovators. He joined the Legomedic project in 2013 to work on continuous crystallization in the team of Prof. B. Scheid.
Marie obtained her Msc. in chemical and process engineering at the Ecole Nationale Supérieure des Industries Chimiques (ENSIC) in Nancy in 2021. After studying for a year in Berlin, she is fluent in Germand and also speaks French and English. Interested in microfluidics, she joined Secoya beginning of 2022.
Obtained a Msc. in bioengineering and biomedical engineering at Sup’ Biotech. After working 5 years as Senior Business Manager Life Sciences, she joined the Secoya team in 2023. Diala is fluent in English, French and Arabic.
Is a professor at the Université Libre de Bruxelles, where he got his PhD in 2004 on theoretical modelling of hydrodynamic instabilities. In 2005, he was awarded the Ilya Prigogine Prize for his PhD dissertation on dissipative wave patterns. In 2007, he got a postdoctoral research position at Harvard University, where he performed research on glass processing in collaboration with Saint-Gobain. He landed an academic position in 2011 at ULB from the National Foundation for Scientific Research (FNRS). His research aims at improving the current expertise in interfacial dynamics and surface rheology, and to make it unique in answering scientific and technological questions applying to material processing and microfluidics, with potential impact in material, pharmaceutical, chemical, biological and medical sciences.
Alex is a natural entrepreneur, born into a long-standing tradition of innovation and success. He started his own profitable venture during his university years. His passion for business creation and excellence led him to invest in several companies and develop them. Alex has a gift for working with and supporting entrepreneurs, enabling them to achieve their goals and to build successful businesses. Following his law studies at KU Leuven, he went on to complete an MBA at the Vlerick School in Belgium, where he honed his skills through his interactions with visiting entrepreneurs and business leaders. He is fluent in English, French and Dutch and speaks German.
Jean-Charles loves creating great corporate strategies with entrepreneurs. He strongly believes in the importance of the human factor for any successful venture. This leads him to build a long-lasting and trustful relationship with entrepreneurs along the path of their equity journeys. Jean-Charles is also passionate about stock market mechanisms and how they contribute to value creation for small and mid caps in the real economy. Having spent more than 8 years at Euronext Stock Exchange in various positions, he gained a wealth of experience in managing IPOs and advising listed companies on how to optimize the benefits of their flotation. Jean-Charles possesses a rare combination of expertise in financial law, finance and strategy, which he loves to share with entrepreneurs for an efficient IPO process. He holds a degree in Law (UCL, Belgium) and an MBA (Solvay Business School, Belgium).
Stéphanie is involved in the field of innovation for over 20 years. She started her career at Genzyme a Sanofi company – the pioneering company in orphan drug development- where she has held various major positions. Among others she has led successfully the launch of two orphan drugs across Europe and has created and led Genzyme patient group relations team for Europe.
These last 10 years Stéphanie has played leading roles in biotech start-up companies being in charge of early and late stage orphan drug commercialisation planning for Europe, Middle-East and Africa region and responsible for the set-up of the European infrastructure/ organisation for North American companies.
She has recently started her own consultancy company providing services to pharmaceuticals companies developing orphan drugs. Stéphanie holds a degree in chemistry- specialisation in biochemistry (UCL- Belgium) and holds a 1-year MBA from Louvain School of Business (UCL).
Dr. Cedric Szpirer earned a PhD in molecular biology from Université Libre de Bruxelles. He was the founder of Delphi Genetics in 2001. He has been Executive & Scientific Director of Delphi Genetics until beginning of 2021 when the company was sold to Catalent. He worked as General Manager for Catalent Belgium until June 2021. He is also the inventor or co-inventor of more than 10 patent families in the field of molecular biology, gene therapy, recombinant productions and DNA engineering and author of several publications in this field.
As founder and CTO of Univercells, José is the architect of highly efficient production processes that will make biologics available and affordable for all.
A recognized technology leader in the biopharmaceutical industry, José brings a strong track record in innovative processes design and successful commercialization.
Previous accomplishments include the start-up of Artelis, where he designed and developed bioreactors that transformed industrial operations – the iCellis system being now considered as standard in the vaccines and gene therapy industry. The technology was industrialized at ATMI LifeSciences and Pall Lifesciences, where José held the position of Cell Culture Technologies Director. Prior to Artelis, José was Head of Viral Vaccine Industrialization at GSK Vaccines.
With a background in Chemical Engineering, Jose’s education includes a PhD in Applied Sciences from the Université Libre de Bruxelles, and an entrepreneurship degree from the Solvay Business School.
Jean-Marie Solvay is a serial entrepreneur in various industries and continents. In 1988, he founded two businesses in the helicopter service industry in the western US of which he was CEO and chief pilot, specializing in forest fire fighting, power line construction and maintenance. In 2000, Jean-Marie sold his aviation activities and invested in the East Berlin real-estate market where he currently manages a portfolio of buildings.
As a member of the board of Solvay S.A. for 29 years (until Mai 2020) and since 2004 as a member of the innovation board, Jean Marie has actively supported research and innovation at Solvay. He is also the chairman of the Solvay family’s shareholder council and member of the Solvac SA board.
Jean-Marie is a member of the Board of the Innovation Fund in Brussels Belgium, a capital venture fund focused on providing financial support to emerging businesses in the chemical industry in Belgium.
He is the chairman of the board of the Solvay International Institutes for Physics and Chemistry. These institutes are a widely known Belgian scientific foundation. They organize periodically the famous counsels for physics and chemistry and supports the Belgium scientific community with activities organized around distinguished researchers.